Clinical Trial Evidence: What the Research Shows Phase 2 trial data published in the NEJM (2023) showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, alongside improvements in blood pressure, lipid profiles, and fasting glucose, though Phase 3 results are still awaited
Most people need 68 sessions initially for visible results
Ozempic and other semaglutide products are prescription medications
A Greek yogurt parfait with berries and chia seeds can work well for breakfast or a light lunch
This biological shift significantly increases the feeling of fullness and suppresses the "hunger hormones" in the brain
A 2007 double-blind, multicenter trial (n=102) showed ALC 1,500 mg/day significantly improved tender point count, total myalgic score, depression, and musculoskeletal pain compared to placebo.[9] A 2015 RCT found ALC 1,500 mg/day comparable to duloxetine 60 mg/day for pain and depression.[8] Most notably, a 2023 RCT demonstrated that adding PEA 1,200 mg/day + ALC 2,000 mg/day to ongoing duloxetine + pregabalin therapy produced significantly greater improvements in Widespread Pain Index, FIQR, and FASmod scores.[7] Role in Treatment: ALC can be used as monotherapy or adjunctive therapy in fibromyalgia